Stockscreener 앱 받기
19.33
0.28%
-0.04
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics stock hits 52-week high at 19.91 USD - Investing.com
Stoke Therapeutics: Vulnerable To Profit Taking (NASDAQ:STOK) - Seeking Alpha
Biogen Partnership and Zorevunersen Data Could Be a Game Changer for Stoke Therapeutics (STOK) - simplywall.st
Will Stoke Therapeutics Inc. bounce back from current supportPortfolio Gains Summary & Real-Time Market Trend Scan - Newser
Price action breakdown for Stoke Therapeutics Inc.Risk Management & High Conviction Trade Alerts - Newser
Institutional scanner results for Stoke Therapeutics Inc.Portfolio Risk Summary & Low Drawdown Momentum Trade Ideas - Newser
Ranking Stoke Therapeutics Inc. among high performing stocks via tools2025 Technical Patterns & Risk Controlled Swing Alerts - Newser
Is Stoke Therapeutics Inc. stock ready for a breakoutJuly 2025 Momentum & Safe Capital Growth Trade Ideas - Newser
Stoke Therapeutics Beats Shareholder Challenge to Board Bylaw - Bloomberg Law News
Will Stoke Therapeutics Inc. Recover After Recent Decline getLinesFromResByArray error: size == 0 - kangso.co.kr
Using economic indicators to assess Stoke Therapeutics Inc. potentialQuarterly Investment Review & Safe Entry Trade Reports - Newser
Gain Therapeutics shares fall 2.17% premarket after Biogen and Stoke Therapeutics present new clinical data. - AInvest
Analyzing drawdowns of Stoke Therapeutics Inc. with statistical toolsPortfolio Risk Summary & Expert Curated Trade Setup Alerts - Newser
Will breakout in Stoke Therapeutics Inc. lead to full recoveryQuarterly Performance Summary & Expert-Curated Trade Recommendations - Newser
Cognition Therapeutics shares rise 1.82% after-hours following positive clinical data presentations by Stoke Therapeutics and Biogen. - AInvest
Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified - simplywall.st
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 49% - 富途牛牛
Biogen, Stoke Therapeutics present data from studies of zorevunersen - TipRanks
Breakthrough: 3-Year Study Shows Biogen's Drug May Modify Dravet Syndrome Disease Course - Stock Titan
Short Interest Drops in Stoke Therapeutics Inc. After RallyJuly 2025 Momentum & Real-Time Volume Triggers - kangso.co.kr
What’s the RSI of Stoke Therapeutics Inc. stockWeekly Gains Summary & Free Fast Entry Momentum Trade Alerts - 더경남뉴스
Aug Catalysts: Will Stoke Therapeutics Inc. stock go up in YEARMarket Risk Report & Precise Trade Entry Recommendations - sundaytimes.kr
What are the analyst revisions for MESAIs Stoke Therapeutics Inc. stock a good investment in YEAR2025 Geopolitical Influence & Reliable Intraday Trade Plans - theviewers.co.kr
Can Stoke Therapeutics Inc. outperform under higher oil pricesJuly 2025 Pullbacks & Risk Managed Investment Entry Signals - theviewers.co.kr
Is Stoke Therapeutics Inc. affected by consumer sentimentQuarterly Portfolio Report & High Return Stock Watch Alerts - theviewers.co.kr
Is Stoke Therapeutics Inc. part of any major indexMarket Performance Report & AI Driven Price Predictions - theviewers.co.kr
Stoke Therapeutics Insider Stock Sales Cause Market Stir - AInvest
Stoke Therapeutics Executives Sell Shares to Cover Tax Liabilities - TradingView
Stoke Therapeutics Executives Sell Shares at $18.24/Share on August 18, 2025. - AInvest
What MACD and RSI say about Stoke Therapeutics Inc.2025 Market Sentiment & Free Technical Confirmation Trade Alerts - Newser
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) - Eastern Progress
Stoke Therapeutics stock hits 52-week high at $18.61 - Investing.com India
Stoke Therapeutics stock hits 52-week high at $18.61 By Investing.com - Investing.com Canada
Stoke Therapeutics shares rise 1.27% intraday after announcing inducement grants to new employees. - AInvest
Multi asset correlation models including Stoke Therapeutics Inc.Trade Ideas & Free Safe Entry Trade Signal Reports - Newser
Stoke Therapeutics shares fall 3.24% premarket after Purcell & Lefkowitz LLP announces shareholder investigation. - AInvest
Analysts Conflicted on These Healthcare Names: Merck & Company (MRK), Stoke Therapeutics (STOK) and Regeneron (REGN) - The Globe and Mail
Stoke Therapeutics' Strategic Stock Grants: Fueling Leadership Stability and Long-Term Value Creation in Biotech - AInvest
Stoke Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News - GuruFocus
Stoke Therapeutics Inc. Approaches Psychological Resistance LevelWeekly Volume Report & Weekly Sector Rotation Insights - classian.co.kr
BTIG Maintains Buy Rating on Stoke Therapeutics with $28 Price Target - AInvest
Purcell & Lefkowitz LLP Investigates Stoke Therapeutics on Shareholder Breach of Fiduciary Duties - AInvest
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) - MarketScreener
Stoke Therapeutics price target lowered to $28 from $29 at BTIG - TipRanks
Stoke Therapeutics stock price target lowered to $28 at BTIG on Zorevunersen data - Investing.com
How Stoke Therapeutics Inc. stock performs during market volatility2025 Top Gainers & Daily Volume Surge Signals - Newser
Watch for Trend Continuation in Stoke Therapeutics Inc. Next WeekQuarterly Trade Report & Free Expert Approved Momentum Trade Ideas - beatles.ru
Building trade automation scripts for Stoke Therapeutics Inc.Market Volume Summary & Safe Capital Growth Tips - Newser
Cantor Fitzgerald Has Positive View of STOK FY2025 Earnings - Defense World
Does Stoke Therapeutics Inc. qualify in momentum factor screeningWeekly Investment Report & Free Reliable Trade Execution Plans - Newser
Stoke Therapeutics Receives Buy Rating from Leerink Partners with $18 Price Target - AInvest
HC Wainwright Analysts Lift Earnings Estimates for STOK - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Defense World
Biogen Shares Surge 2.71% on $230M Volume Boosted by Pipeline Progress Ranks 444th in Market Activity - AInvest
Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) By Investing.com - Investing.com Nigeria
Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) - Investing.com
0.89%
7.86%
자본화:
|
볼륨(24시간):